Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects

ConclusionsSeveral polymorphisms can explain differences in the pharmacokinetics, pharmacodynamics, and safety of olanzapine in healthy subjects. Whether these genetic factors influence the risk of therapeutic failure or tolerability in patients remains to be established. Copyright © 2013 John Wiley & Sons, Ltd.

Source: Human Psychopharmacology: Clinical and Experimental - April 5, 2013 Category: Psychiatry Authors: Teresa Cabaleiro, Rosario López‐Rodríguez, Dolores Ochoa, Manuel Román, Jesús Novalbos, Francisco Abad‐Santos Tags: Research Article Source Type: research